2020-04-13T16:58:56-07:00 2019-06-30 990 2018-07-01 030485196 MYELIN REPAIR FOUNDATION INC MYEL 20111 Edinburgh Drive Saratoga CA 95070 Scott Johnson Chief Executive Officer 4088885542 2020-02-28 69.181.110.214 2018 2020-09-23 17:36:50Z Scott Johnson 20111 Edinburgh Drive Saratoga CA 95070 344205 0 X myelinrepair.org X 2002 CA Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by MS 5 4 1 4 6926 0 1007500 287392 0 7293 70054 0 1077554 294685 306439 338524 0 166715 157202 0 29107 116030 42674 589184 538400 488370 -243715 1627215 1552624 299317 468441 1327898 1084183 Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. The MRF is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 0 0 473863 338524 0 Bio fluid and imaging grants for experiments to identify potential biomarkers of myelin repair in multiple sclerosis. MRF has funded experiments and analysis in the current year that include the following. 1. looking into in MS patients plasma for lipids that correlate with repair/damage (myelin is 80%lipid) 2. measuring MS related neurodegeneration utilizing plasmaderived neuronal ECVs 3.using MP2RAGE data as a potential marker of myelin status in MS white matter lesions 4.determine if fluid-based markers of synatogenesis can be an indicator of myelin repair 5.Explore the use of ECVs as a biomaker of blood brain barrier dysfunction in MS 6.charaterize ECVs from astrocytes from human Induced Pluripotent Stem Cells 0 0 0 473863 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1 0 0 CA X Louise Savoie 4088885542 2198 Hillstone Dr San Jose CA 95138 Scott Johnson CEO 30 X X 120000 0 0 Casey Mcglynn Director 1 0 X 0 0 0 Andy Cates Director 1 0 X 0 0 0 Bobby Mehta Director 1 0 X 0 0 0 Jim Gidwitz Director 1 0 X 0 0 0 120000 0 0 1 0 0 0 0 0 0 0 0 0 287392 0 287392 0 6926 0 6926 0 0 0 0 0 0 0 0 0 0 0 49887 0 49520 0 367 0 367 367 0 0 0 0 294685 367 6926 0 155000 155000 0 0 183524 183524 0 0 120000 78000 20240 21760 0 0 0 0 27588 17932 4966 4690 9614 6250 1730 1634 7528 7528 0 26338 26338 5684 3695 966 1023 3124 3124 538400 473863 35430 29107 994215 18563 909007 633000 622000 3054 1627215 1552624 299317 468441 299317 468441 X 1327898 1084183 0 0 0 0 1327898 1084183 1627215 1552624 -243715 0 0 0 0 0 X 0 0 0 X 2660019 216766 50000 1007500 287392 4221677 2660019 216766 50000 1007500 287392 4221677 2750000 1471677 392 6926 7318 106579 70054 176633 4405628 0 0.33404 0.5382 X Schedule A, Part II, Line 10 Return of previous years unused grant RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 Europe (including Iceland and Greenland) 0 0 183525 0 0 183525 Europe (including Iceland and Greenland) MRF provides grant to Dr. Mika Simons at Technical University Munich to look in MS patient's plasma for lipids that correlate with repair/damage (myelin is 80% lipid) 50000 cash progress payments 0 contractual amount Europe (including Iceland and Greenland) MRF sponsors experiment in Germany to determine if fluid based markers of synaptogenesis can be an indicator of myelin repair 50000 cash progress payments 0 contractual amount Europe (including Iceland and Greenland) MRF begins collaboration at Lausanne University in Switzerland to characterize EVs from human astrocytes 7726 cash progress payment 0 contractual amount Europe (including Iceland and Greenland) MRF contracts with Biognosys to perform protein profiling of human CSF samples from our collaborations in Sweden and Germany 75799 cash progress payments 0 contractual amount 3 4 0 0 0 0 0 0 Schedule F, Part I, Line 2 Grants outside the United States are treated the same as grants within the United States with regular required reports and conversations with recipients 1 Cornell University 102 Prospect Street Ithaca NY 14850 150532082 50000 0 contractual amount 0 MRF supports Cornell study to explore the use of ECVs as a biomarker of blood brain barrier dysfunction in MS John Hopkins School of Medicine 12529 Collections Center Drive Chicago IL 60693 520595110 50000 contractual amount Funding John Hopkins University to measure MS related neurodegeneration utilizing plasma derived neuronal ECVs National Institute of Neurological Disorders 6001 Executive Blvd Room 3280 Rockville MD 20852 520858115 50000 Contractual amount MRF funds work at NIH to reveal if MP2RAGE data provide enough brain tissue differentiation to be a marker of myelin status in MS lessions 4 0 Schedule I, Part I, Line 2 The Universities are subject to terms and conditions of the sponsored research agreement between the Universities and the MRF. The Researchers' work are reviewed by the MRF commitee and by the MRF President. Form 990, Part VI, Section A, Line 9 MRF External Board members and their addresses; 1.Andy Cates 429 N Main street, suite 100 Memphis, TN 38103, 2. Jim Gidwitz 440 S LaSalle, suite 3100, Chicago IL 60605-5020 3. Casey McGlynn 650 Page Mill Road, Palo Alto, CA 94304-1001 4.Bobby Mehta 159 E Walton Street, Chicago IL 60611 Form 990, Part VI, Section B, Line 11b Form 990 is reviewed by the CEO and once the CEO approves the form 990 is then forwarded to the board members for their review prior to filing. Board members are encouraged to review and to forward their questions, if any, to the CEO. Form 990, Part VI, Section B, Line 12c Officers, directors and key employees are covered. Any and all conflicts are reviewed by disinterested board members and, if needed, by legal counsel. Persons with a conflict of interest will be restricted from making key decisions for MRF as they relate to the interest unless otherwise approved by the majority of the disinterested board of directors Form 990, Part VI, Section B, Line 15 CEO Compensation is determined by the board of directors and is the only paid position. The remaining officers are not compensated. Form 990, Part VI, Section C, Line 19 Financial Statements, governing documents and policies are available upon request for the same period of time set forth in Sec. 6104(D)